Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

499.17 +38.30 (+8.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
72 73 Next >
News headline image
Peering Into Vertex Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy? ↗
It looks like Vertex's experimental new therapy could become a functional cure for lots of people with diabetes. 
Via The Motley Fool
News headline image
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead ↗
Lilly is a good pick...but this one is better. 
Via The Motley Fool
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX. ↗
NASDAQ:VRTX is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
13 Analysts Have This To Say About Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)? ↗
Why NASDAQ:VRTX Stands Out as a Quality Stock. 
Via Chartmill
News headline image
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation ↗
Evergreen business models make it easier to hold for the long run. 
Via The Motley Fool
News headline image
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades' ↗
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having... 
Via Benzinga
News headline image
3 Growth Stocks You Can Buy Right Now Without Any Hesitation ↗
Want peace of mind about your investments? Consider these great stocks. 
Via The Motley Fool
News headline image
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
This Is What Whales Are Betting On Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Expectations For Vertex Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
2 Healthcare Stocks to Buy Hand Over Fist in June ↗
They both have pretty impressive pasts, and their prospects look just as bright. 
Via The Motley Fool
News headline image
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO ↗
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets
News headline image
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought ↗
These companies could generate explosive growth over time. 
Via The Motley Fool
News headline image
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst ↗
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety . 
Via Benzinga
News headline image
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. ↗
NASDAQ:VRTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Large Cap BIopharmaceuticals Overview ↗
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
News headline image
3 No-Brainer Stocks to Buy in June ↗
Now is the time to invest in these great stocks. 
Via The Motley Fool
News headline image
5 Top Stocks to Buy in June ↗
This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer. 
Via The Motley Fool
News headline image
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points ↗
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
News headline image
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks ↗
It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly... 
Via Talk Markets
News headline image
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists ↗
Vertex stock was one of a select group of eight that made it onto IBD top-stocks lists Friday. The big pharma is near its all-time high. 
Via Investor's Business Daily
News headline image
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals? ↗
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat. 
Via The Motley Fool
News headline image
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic ↗
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function. 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.